MyMetabolon Login
© 2020 Metabolon, Inc. All rights reserved.
Metabolon Metabolon
  • Metabolomics
    • About Metabolomics
    • Our Process
    • Technology & Knowledgebase
    • Setting the Standard: The 4Cs
    • Our Latest Insights
  • Solutions
    • Column 1
      • Products & Services
        • Global Metabolomics
        • Lipidomics
        • Targeted Assays
        • Study Design & Consulting
        • Sample Preparation & Handling
        • Study Success Sample Handling Kit
        • Reporting & Interpretation
        • Bioinformatics
        • MyMetabolon Client Portal
    • Column 2
      • By Research & Development Phase
        • Discovery & Target Selection
        • Lead Candidate Selection
        • Preclinical
        • Clinical Development
        • Manufacturing & Bioprocessing
    • Column 3
      • By Therapeutic Area
        • Cardiovascular Disease
        • COVID-19
        • Diabetes
        • Gastrointestinal
        • Liver Disease
        • Microbiome
        • Neuroscience
        • Oncology
        • Renal & Urological Disorders
        • Respiratory Disorders
    • Column 4
      • By Sector
        • Academic
        • Agriculture
        • Biotech / Pharmaceutical
        • Precision Medicine
        • Nutrition
        • Personal Care & Cosmetics
        • Population Health
        • Veterinary & Animal Health
  • Insights
    • Our Latest Insights
    • Blog
    • News & Events
  • Resources
    • Resource Library
    • Client Stories
    • COVID-19
  • Company
    • About Us
    • Working With Us (FAQ)
    • Leadership
    • Careers
    • Strategic Partnering
    • News & Events
    • Contact Us
MyMetabolon
Demo Our Data
Metabolon
Demo Our Data

Company News & Press

National Institute of Allergy and Infectious Disease (NIAID) Selects Metabolon, Inc. for COVID-19 Study
23 November 2020

National Institute of Allergy and Infectious Disease (NIAID) Selects Metabolon, Inc. for COVID-19 Study

“We are honored to partner with NIAID and Metabolon in this effort to define how the human response to SARS-CoV-2 correlates to COVID severity and outcome. Metabolic features of the immune responses are increasingly recognized as pivotal to disease and health, and we are fortunate to have Metabolon’s excellent team by our side as we undertake this critical work.” – Dr. Ofer Levy, Director of the Precision Vaccines Program (PVP) at Boston Children’s Hospital
Metabolon, Inc. Announces $72 Million in Debt and Equity Financing to Accelerate Advancements in Precision Medicine and Innovative Drug Development Technologies
23 September 2020

Metabolon, Inc. Announces $72 Million in Debt and Equity Financing to Accelerate Advancements in Precision Medicine and Innovative Drug Development Technologies

New and existing investors contributed to biotech’s largest ever capital raise; company also announced appointment of Robert A. Cascella, Chief Business Leader, Precision Diagnostics, and Executive Vice President of Phillips, as one of three independent members of the Metabolon Board of Directors.
Metabolon, Inc. Joins SOPHIA, International Research Consortium
6 August 2020

Metabolon, Inc. Joins SOPHIA, International Research Consortium

Metabolon will perform metabolomics on study participants as part of the five-year longitudinal study to improve risk assessment of complications of obesity, supporting greater understanding in patient stratification for the right treatment depending on metabolic profiles.
Metabolon Announces Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany
3 August 2020

Metabolon Announces Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany

Metabolomic insights will support the leading science and technology company in advancement of its drug early development programs across therapeutic areas.
Metabolon, Inc. and DNA Genotek Collaborate on First Ambient-Temperature Microbiome Sampling Solution for Metabolomics
22 June 2020

Metabolon, Inc. and DNA Genotek Collaborate on First Ambient-Temperature Microbiome Sampling Solution for Metabolomics

OMNImet™·GUT expands access to critical metabolomic analysis with development of in-home fecal collection device – the first device for in-home collection and ambient-temperature storage and shipping of fecal samples for metabolomics, to the research market.
Enlightening a Company, By Design
20 June 2020

Enlightening a Company, By Design

Metabolon, Inc. has unveiled a new brand rooted in its 20-year history as a revolutionary leader in metabolomics. The company's corporate mission to "enlighten life and enable a better, healthier world," reflects the unique value and urgency of Precision Metabolomics™ in expanding and accelerating discovery across life sciences research.
Metabolon Wins Five Year Contract with U.S. Army Research Institute of Environmental Medicine
20 May 2020

Metabolon Wins Five Year Contract with U.S. Army Research Institute of Environmental Medicine

Metabolomic insights will support Army’s research into Warfighter health-readiness and optimal performance. Metabolon, Inc., the global leader in metabolomics, has been selected by the U.S. Army Research Institute of Environmental Medicine (USARIEM), to analyze the metabolic profiles of military personnel in a research program being conducted by the Military Nutrition Division.
Metabolon, Inc. Appoints Karl Bradshaw, Ph.D., to Lead Biopharma Strategy and Partnering
4 October 2019

Metabolon, Inc. Appoints Karl Bradshaw, Ph.D., to Lead Biopharma Strategy and Partnering

“We welcome Karl at an exciting time when Metabolon is implementing new strategies to increase our growth and prominence as the biotech partner capable of addressing the most difficult questions in the life sciences through our unmatched approach to metabolomics,” said Rohan Hastie, Ph.D., President and CEO, Metabolon.
New partnership leveraging metabolomics to uncover reasons for frailty in aging populations
10 July 2019

New partnership leveraging metabolomics to uncover reasons for frailty in aging populations

Metabolon, Inc. joins forces with three Canadian research groups – The Canadian Frailty Network, the Canadian Longitudinal Study of Aging (CLSA) and the McMaster Institute for Research on Aging (MIRA) – to discover the frailty biomarkers that may shed light on why some people become frail, determine the severity of frailty and what can be done to help avoid the condition.
Metabolon to Provide Metabolomic Profiling for the US Veterans Administration Million Veteran Program
19 April 2019

Metabolon to Provide Metabolomic Profiling for the US Veterans Administration Million Veteran Program

The U.S. Department of Veterans Affairs (VA) has selected the Company through its alliance with AKESOgen, a leader in genomics, to perform large-scale metabolomic profiling on biological samples from U.S. veterans as part of the Million Veteran Program (MVP).
Load more

Find Us at These Events

National Institute of Allergy and Infectious Disease (NIAID) Selects Metabolon, Inc. for COVID-19 Study
23 November 2020

National Institute of Allergy and Infectious Disease (NIAID) Selects Metabolon, Inc. for COVID-19 Study

“We are honored to partner with NIAID and Metabolon in this effort to define how the human response to SARS-CoV-2 correlates to COVID severity and outcome. Metabolic features of the immune responses are increasingly recognized as pivotal to disease and health, and we are fortunate to have Metabolon’s excellent team by our side as we undertake this critical work.” – Dr. Ofer Levy, Director of the Precision Vaccines Program (PVP) at Boston Children’s Hospital
Metabolon, Inc. Announces $72 Million in Debt and Equity Financing to Accelerate Advancements in Precision Medicine and Innovative Drug Development Technologies
23 September 2020

Metabolon, Inc. Announces $72 Million in Debt and Equity Financing to Accelerate Advancements in Precision Medicine and Innovative Drug Development Technologies

New and existing investors contributed to biotech’s largest ever capital raise; company also announced appointment of Robert A. Cascella, Chief Business Leader, Precision Diagnostics, and Executive Vice President of Phillips, as one of three independent members of the Metabolon Board of Directors.
Metabolon, Inc. Joins SOPHIA, International Research Consortium
6 August 2020

Metabolon, Inc. Joins SOPHIA, International Research Consortium

Metabolon will perform metabolomics on study participants as part of the five-year longitudinal study to improve risk assessment of complications of obesity, supporting greater understanding in patient stratification for the right treatment depending on metabolic profiles.
Metabolon Announces Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany
3 August 2020

Metabolon Announces Multi-Year Collaboration with Merck KGaA, Darmstadt, Germany

Metabolomic insights will support the leading science and technology company in advancement of its drug early development programs across therapeutic areas.
Metabolon, Inc. and DNA Genotek Collaborate on First Ambient-Temperature Microbiome Sampling Solution for Metabolomics
22 June 2020

Metabolon, Inc. and DNA Genotek Collaborate on First Ambient-Temperature Microbiome Sampling Solution for Metabolomics

OMNImet™·GUT expands access to critical metabolomic analysis with development of in-home fecal collection device – the first device for in-home collection and ambient-temperature storage and shipping of fecal samples for metabolomics, to the research market.
Enlightening a Company, By Design
20 June 2020

Enlightening a Company, By Design

Metabolon, Inc. has unveiled a new brand rooted in its 20-year history as a revolutionary leader in metabolomics. The company's corporate mission to "enlighten life and enable a better, healthier world," reflects the unique value and urgency of Precision Metabolomics™ in expanding and accelerating discovery across life sciences research.
Metabolon Wins Five Year Contract with U.S. Army Research Institute of Environmental Medicine
20 May 2020

Metabolon Wins Five Year Contract with U.S. Army Research Institute of Environmental Medicine

Metabolomic insights will support Army’s research into Warfighter health-readiness and optimal performance. Metabolon, Inc., the global leader in metabolomics, has been selected by the U.S. Army Research Institute of Environmental Medicine (USARIEM), to analyze the metabolic profiles of military personnel in a research program being conducted by the Military Nutrition Division.
Metabolon, Inc. Appoints Karl Bradshaw, Ph.D., to Lead Biopharma Strategy and Partnering
4 October 2019

Metabolon, Inc. Appoints Karl Bradshaw, Ph.D., to Lead Biopharma Strategy and Partnering

“We welcome Karl at an exciting time when Metabolon is implementing new strategies to increase our growth and prominence as the biotech partner capable of addressing the most difficult questions in the life sciences through our unmatched approach to metabolomics,” said Rohan Hastie, Ph.D., President and CEO, Metabolon.
New partnership leveraging metabolomics to uncover reasons for frailty in aging populations
10 July 2019

New partnership leveraging metabolomics to uncover reasons for frailty in aging populations

Metabolon, Inc. joins forces with three Canadian research groups – The Canadian Frailty Network, the Canadian Longitudinal Study of Aging (CLSA) and the McMaster Institute for Research on Aging (MIRA) – to discover the frailty biomarkers that may shed light on why some people become frail, determine the severity of frailty and what can be done to help avoid the condition.
Metabolon to Provide Metabolomic Profiling for the US Veterans Administration Million Veteran Program
19 April 2019

Metabolon to Provide Metabolomic Profiling for the US Veterans Administration Million Veteran Program

The U.S. Department of Veterans Affairs (VA) has selected the Company through its alliance with AKESOgen, a leader in genomics, to perform large-scale metabolomic profiling on biological samples from U.S. veterans as part of the Million Veteran Program (MVP).
Load more

Enlighten your research,
accelerate your discovery.

Demo Our Data
or Talk With an Expert

Metabolomics

  • About Metabolomics
  • Our Process
  • Technology & Knowledgebase
  • Setting the Standard: The 4Cs
  • Insights & Discoveries

Solutions

  • Products & Services
  • By Research & Development Phase
  • By Therapeutic Area
  • By Sector

Insights

  • Our Latest Insights
  • Blog
  • News & Events

Resources

  • Resource Library
  • Client Stories
  • COVID-19

Company

  • About Us
  • Working With Us (FAQ)
  • Leadership
  • Careers
  • Strategic Partnering
  • News & Events
  • Contact Us
Metabolon - Logo - Enlightening Life

Metabolon provides actionable biological insights to answer the toughest questions in life sciences research and drug development.

© 2021 Metabolon, Inc. All rights reserved. Privacy & Terms

in
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Cookie settingsACCEPT
Manage consent

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled

Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.

Non-necessary

Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.